Revance Therapeutics Investor Relations Material

Revance Therapeutics, Inc. is a biotechnology company that engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead product candidate is Gimoti, which addresses the under-diagnosed condition of excessive eyelid perspiration known as Frey syndrome through its proprietary intranasal formulation of topically applied tacrolimus. Revance also provides a range of services to assist clients in human proof-of-concept research involving its approved products. These services include regulatory submissions, clinical study design and management; clinical data collection and statistical analysis; drafting publication texts; and establishment of intellectual property rights related to these studies.